Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium to Advance AI-Driven Drug Discovery Ginkgo Datapoints, an offering of Ginkgo Bioworks, and Apheris GmbH have announced the launch of the Antibody Developability Consortium, a new industry collaboration focused on improving the…
SCIEX Expands BioPhase 8800 Capabilities to Support Faster, More Automated CE Workflows SCIEX, a Danaher company and a provider of analytical technologies for the life sciences, has announced new capillary electrophoresis (CE) capabilities for its BioPhase 8800 system. The latest…
Bristol Myers Squibb Reports Phase 3 EXCALIBER-RRMM Results Showing Higher MRD-Negative Responses With ZENBEXUS in Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) has announced the first presentation of detailed results from the prespecified analysis of its pivotal…
Countable Labs Enters Clinical Market With Ancora Oncology Assays Powered by Single-Molecule PCR Technology Countable Labs, a developer of advanced molecular testing technologies, has announced its entry into the clinical market with the launch of its Ancora assays for oncology…
Scientific Review Identifies Selenium Sulfide and Zinc Pyrithione as Evidence-Based Dandruff Treatments Scientists from Head & Shoulders and dermatology experts reviewed the latest clinical evidence on dandruff treatment during the September 2026 Science of Skin Summit in Austin, Texas, highlighting…
Allotera Therapeutics Opens MRD-Positive Cohort in Pivotal T-RRex Study of Sofi-cel for T-ALL and T-LBL Allotera Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, announced the opening of a new minimal residual disease (MRD)-positive…
BioIVT to Showcase Translational Research Strategies for Metabolic Disease, GLP-1 Therapies and Emerging Drug Development Models BioIVT, a global research partner and biospecimen solutions provider supporting drug and diagnostic development, is preparing to highlight new research and practical approaches for…
Pilatus Biosciences to Present Phase 1 PLT012 Clinical Trial at ESMO Congress 2026 Pilatus Biosciences, a biopharmaceutical company focused on developing novel metabolic checkpoint immunotherapies for cancer, announced that its ongoing Phase 1 clinical trial of PLT012 has been selected…
Aurion Biotech Completes Enrollment in U.S. Phase 3 ASTRA Study of Regenerative Cell Therapy AURN001 Aurion Biotech, Inc., a commercial-stage regenerative cell therapy company focused on restoring vision, has announced the completion of patient enrollment in its U.S. ASTRA Phase…
Establishment Labs Presents New Breast Tissue Preservation Data and Expands Minimally Invasive Platform at WSEI Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on advancing women’s health and wellness, particularly in breast aesthetics and reconstruction, has…
Alkermes Reports Positive Phase 1 Results for Investigational Orexin 2 Receptor Agonist ALKS 7290 in Adult ADHD Alkermes plc (Nasdaq: ALKS) has announced positive topline results from a Phase 1 proof-of-concept study evaluating ALKS 7290, a novel investigational orexin 2…
Iambic Launches Enchant v3 to Advance AI-Driven End-to-End Drug Discovery Iambic, a clinical-stage life science and technology company developing novel medicines through an artificial intelligence-driven platform, has unveiled Enchant v3, the latest generation of its multimodal transformer model designed to…